Immunity to RBD of SARS-CoV-2 diminishes by 6 months post-vaccination in those with pre-existing Ad5 antibodies.
ADENOVIRUS, SEVERE ACUTE RESPIRATORY SYNDROME, CORONAVIRUS
Pearson’s correlation coefficient between GMTs versus anti-Ad5 antibodies (ADENOVAB) in response to anti-RBD and anti-S protein antibodies as well as neutralising SARS-CoV-2 antibodies (NAbs) on Day 0, Day 14, Day 28 and Month 6 after vaccination. Participants were from the FAS for immunogenicity analysis population that received the Ad5-nCoV vaccine and had pre-existing Ad5 antibodies (n = 317). The correlation coefficients with 95% CI are shown. Ad5, adenovirus type-5; CI, confidence interval; RBD, receptor binding domain; S, spike; SARS-CoV 2, severe acute respiratory syndrome coronavirus 2.The effect of the vaccination on cellular immune responses was studied in a subgroup of 69 participants recruited by the Moscow clinic site (Ad5-nCoV group, n = 50 volunteers; Placebo group, n = 19). The presence of SARS-CoV-2 specific CD8